Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024blacksmithmed2024-04-09T12:23:24-07:0004.10.2024|
Blacksmith Medicines to Present at the 23rd Annual Needham Healthcare Conferenceblacksmithmed2024-04-02T16:19:25-07:0004.03.2024|
Blacksmith Medicines to Present at the Gordon Research Conference on New Antibacterial Discovery and Developmentblacksmithmed2024-03-19T06:59:20-07:0003.19.2024|
Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024blacksmithmed2024-03-06T07:00:33-08:0003.06.2024|
Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibioticblacksmithmed2024-02-20T10:03:06-08:0002.21.2024|
Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibioticsblacksmithmed2024-02-13T09:36:54-08:0002.14.2024|
Blacksmith Medicines announces oncology scientific advisorsblacksmithmed2023-01-05T06:02:55-08:0001.05.2023|
Blacksmith returns to Forge as companies remerge to hammer out metalloenzyme medicinesblacksmithmed2023-01-04T13:13:52-08:0001.03.2023|Tags: Fierce Biotech|
Forge spinoff Blacksmith Medicines merges back into company two years after launch, but details are slimblacksmithmed2023-01-04T13:13:13-08:0001.03.2023|Tags: Endpoints News|
Blacksmith Medicines Announces Merger With Forge Therapeutics to Create Leading Company Developing Medicines Targeting Metalloenzymesblacksmithmed2023-01-04T13:12:52-08:0001.03.2023|Tags: BioSpace|
